BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (JULY AUGUST 2020)

COVID 19 and Liver - Current Status

Neeraj.V1 & K.R.Vinayakumar2

Introduction: The pandemic of corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona virus2(SARS CoV-2). Though, predominantly a respiratory virus, multiorgan involvement leading to mortality has been well documented. Liver involvement in COVID-19 is being greatly discussed at present. This article aims to highlight the various mechanisms of liver involvement in COVID-19. Liver injury in COVID-19 is likely to be due to various mechanisms like virus directly infiltrating hepatocytes (cytopathic effect), secondary causes like hypoxic injury, drugs and bystander hepatitis. It also stresses on the point that liver injury is directly proportional to the severity of the disease. Though predominantly a respiratory virus with droplet and contact transmission, faeco-oral transmission is also present. This review also focuses on the epidemiology, virology, immunopathogenesis, clinical features and the implications of various groups of chronic liver disease due to COVID-19 with the available literature so far. So far, only symptomatic treatment is being carried out for liver injury in COVID-19. Finally, this article also put forward some recommendations that can be followed in clinical practice as per the existing guidelines.

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.